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Background: Azathioprine (AZA) and mercaptopurine (MP) are the cornerstone of
steroid‐sparing strategies in autoimmune hepatitis (AIH). Up to 20% of patients do
not tolerate or respond to these regimens.
Aim: To evaluate retrospectively the tolerability and efficacy of tioguanine (thio-
guanine) (TG) therapy in selected patients with AIH and AIH variant syndromes.
Methods: Records of 52 patients who received TG therapy were retrieved from
nine hospitals in the Netherlands. Indications for TG treatment were intolerable
side effects on AZA or MP (n = 38), insufficient response (n = 11) or first‐line treat-
ment (n = 3). Treatment efficacy was defined as normalisation of serum amino-
transferases and serum immunoglobulin G.
Results: No serious adverse events occurred in patients treated with TG during a
median follow‐up of 18 months (range 1‐194). Treatment was well tolerated in 41
patients (79%), whereas four had tolerable (8%) and seven (13%) intolerable side
effects. Thirty‐eight patients were treated with TG after intolerable side effects on
AZA or MP; 29 patients continued TG therapy of whom 24 (83%) achieved com-
plete biochemical remission, four (14%) had incomplete and one (3%) had no
response; nine discontinued treatment. Seven of 11 patients with insufficient
response to AZA or MP were responsive to TG, three with complete and four with
incomplete biochemical remission; four discontinued due to intolerance (n = 2) and
non‐response (n = 2). TG was effective in all AIH patients as first‐line maintenance
treatment.
Conclusion: In our retrospective review of TG therapy in selected patients with
AIH or AIH variants who previously failed on AZA or MP, TG appeared tolerable
with biochemical efficacy.
The Handling Editor for this article was Professor Stephen Harrison, and it was accepted
for publication after full peer-review.
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1 | INTRODUCTION
Autoimmune hepatitis (AIH) is an immune‐mediated inflammation of
unknown aetiology primarily targeting hepatocytes, usually requiring
lifelong immunosuppressive therapy. Treatment is aimed to prevent
disease relapse, relief symptoms and achieve complete biochemical
and histological normalisation in order to prevent progression to
fibrosis, cirrhosis and end‐stage liver failure requiring liver transplan-
tation.1 Remission is induced using prednisone and often maintained
by a corticosteroid‐saving regime using thiopurines: azathioprine
(AZA) or mercaptopurine (MP).2 Unfortunately, up to 20% of patients
do not respond to or tolerate these conventional thiopurines.3 Cur-
rently, rescue medications are limited to mycophenolate mofetil,
tacrolimus and ciclosporin. The European AIH guideline commemo-
rate states that patients intolerant to AZA can be offered tioguanine
(TG) therapy as alternative to mycophenolate mofetil, although there
is only anecdotic evidence available to support its use.1
Tioguanine, a rediscovered thiopurine for inflammatory bowel
disease can be interchanged with AZA and MP.4,5 Based on a single
study addressing potential side effects related to TG use, there has
been initial concern about the safety of this drug,6 yet well‐designed
additional studies in different cohorts of inflammatory bowel disease
patients have not found evidence to support this assumption.7
Azathioprine and MP are metabolized by a shared pathway via
thiopurine S‐methyltransferase, into hepatotoxic breakdown metabo-
lites 6‐methyl MP and by other enzymatic steps into the pharmaco-
logically active compound 6‐tioguaninenucleotide (6‐TGN). TG is
metabolized directly to 6‐TGN and to 6‐methyltioguanine, the latter
also by thiopurine S‐methyltransferase. Deficient forms of thiopurine
S‐methyltransferase leads to toxic levels of 6‐TGN when a patient is
on TG therapy, causing bone marrow suppression. However, the
absolute burden of methylated side products is much lower during
use of TG when compared to the larger thiopurines AZA and MP.
Hence, TG therapy might be as effective as other thiopurines, but
be better tolerated in the treatment of AIH.
In 2005, our group published the first data on TG therapy in
three AIH patients,8 and more recently another group performed a
single ‐centre study in a small and heterogeneous group of patients
with AIH and AIH variant syndrome.9 To extend the experience with
TG therapy in AIH patients, we have been collecting data on a
national level over a 17‐year period, in the Netherlands. Here, we
report the tolerability, clinical efficacy, safety and steroid‐reduction
of TG therapy in 52 patients with AIH or AIH variant syndromes.
2 | METHODS
2.1 | Study population
Patients were identified by sending an inquiry to hepatogastroen-
terologists in 37 hospitals in the Netherlands in collaboration with
the Dutch Autoimmune Hepatitis Group. A total of 26 (70%) hospi-
tals responded to the questionnaire (19 referral, 7 tertiary). The
study protocol (number 2008.84) was approved by the ethics
committee of the VU University Medical Center. Patient data was
anonymously provided by the treating physicians.
Patients with a clinical diagnosis of AIH who were actively, or
had been, treated with TG were identified in six referral hospitals
and three tertiary centres. The diagnostic post‐treatment revised
International AIH Group scores were calculated.10 All were initiated
on TG therapy between 2001 and 2017 and followed until February
2018 or until TG therapy was discontinued. Three thiopurine naïve
AIH patients were treated with TG therapy as first‐line maintenance
treatment. Thirty‐nine AIH and 10 AIH variant syndrome patients
were switched after previous failure on AZA or MP therapy. The
reasons for conventional thiopurine failure and switching to TG ther-
apy were determined by the attending physician and include intoler-
ance (including toxic 6‐methyl MP levels) or insufficient response
(failure to achieve or maintain remission).
The AIH variant with features of primary biliary cholangitis (AIH‐
PBC) was defined according to the “Paris criteria as AIH with an
anti‐mitochondrial antibodies (AMA) titer of >1:80 in combination
with compatible histology”.11 AMA negative AIH patients with clini-
cal and histopathological features of PBC were defined as “AMA
negative AIH‐PBC”, formerly known as autoimmune cholangitis. AIH
with concurrent primary sclerosing cholangitis (AIH‐PSC) was defined
as AIH with typical findings of PSC on imaging (magnetic resonance
cholangiopancreatography/endoscopic retrograde cholangiopancre-
atography) and/or a compatible histology.12,13
2.2 | Adverse events
Patient records were analysed for (serious) adverse events (i.e. hospi-
tal admissions, acute pancreatitis, side effects). Myelotoxicity was
defined as thrombocytopenia (platelet count of <150 × 109/L), leu-
copenia (white blood cell count of <4.0 × 109/L) or anaemia (female:
haemoglobin <7.5 mmol/L, male: haemoglobin <8.5 mmol/L). One
hepatopathologist assessed the majority of follow‐up biopsies; nodu-
lar regenerative hyperplasia was defined according to the consensus
criteria on the existing histopathologic diagnosis of nodular regenera-
tive hyperplasia by Jharap et al.14 Abdominal imaging reports and
gastroscopy reports were assessed for signs of portal hypertension.
2.3 | Efficacy
Complete biochemical remission was defined as serum alanine amino-
transferase (ALT), serum aspartate aminotransferase and, when available,
serum immunoglobulin G (IgG) within the normal range. Incomplete
response was defined as an ALT of >1 and <2 times the upper limit of
normal and nonresponse as an ALT of >2 times the upper limit of nor-
mal.1 Biochemical relapse was defined as an increase of ALT >3 times
the upper limit of normal or an increase of IgG to >20 g/L.1,15
Sparing of glucocorticosteroid was considered successful if the
dose could be decreased with at least 25% per day with sustained
remission or biochemical improvement. Cirrhosis and inflammatory
activation were histologically assessed according to the Scheuer clas-
sification for grading and staging of chronic hepatitis.16 Drug survival
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was defined as continuation of TG therapy, patients who were
offered a controlled trial of withdrawal were censored at the date
TG was stopped. Treatment failure was defined as discontinuation of
TG therapy for any other reason.
2.4 | Statistical analysis
Statistical analysis was performed with IBM SPSS Statistics for Win-
dows, version 22, IBM Corp., Armonk, NY, USA. Graphs were com-
puted with GraphPad Prism for Windows, version 7.02, GraphPad
Software, La Jolla California, USA. The binominal McNemar test was
used to compare the number of patients reaching complete bio-
chemical remission versus patients who did not reach complete bio-
chemical remission. Patients with ongoing treatment were censored
at the date of last follow‐up. Categorical variables were compared
between two groups using the two‐sided Fisher's exact test. Ordinal
and continuous variables were compared between two groups with
the Mann‐Whitney test (nonparametric). In case three groups were
compared, ANOVA was used for continuous variables with a normal
distribution. For nonnormally distributed variables the Kruskal‐Wallis
test was used. Post‐hoc analyses for correction of multiple testing
were performed with the Bonferroni in case of a parametric test and
Dunn‐Bonferroni following nonparametric tests. The significance
level (α‐level) was set at ≤0.05. Normally distributed variables were
described as mean with SD, not‐normally distributed variables were
described as median with range or interquartile range (IQR) if stated.
3 | RESULTS
A total of 52 patients including AIH (n = 39) and AIH variant syn-
drome (n = 10) patients who were treated with TG as rescue treat-
ment after failing on AZA or MP as well as three thiopurine‐naïve AIH
patients who were treated with TG as first‐line therapy were included
in this study. Characteristics and treatment details are summarised in
Table 1.
3.1 | Adverse events
Tioguanine therapy (20 mg/day, range: 10‐24 mg/day) was well‐toler-
ated in 41 (79%) patients, whereas four experienced tolerable (8%)
and seven (13%) experienced intolerable side effects. A description
of the adverse events reported on previous AZA and MP (44 of 49
patients; 90%) and those reported on subsequent TG therapy is pro-
vided in Table 2. Complaints of arthralgia recurred in one patient
after switching to TG therapy, whereas all other patient‐reported
side effects on TG therapy differed from those reported on the origi-
nal thiopurine. Six patients had severe myelosuppression on AZA or
MP; switching to TG therapy resulted in normalisation of white
blood cell count, haemoglobin and thrombocytes in five patients and
in one patient leukopenia (with levels between 3.0 and 4.0 × 109/L)
persisted. No serious adverse events (i.e. pancreatitis), requiring hos-
pitalisation or critical care were observed in this study. Four patients
with established cirrhosis prior to TG therapy all showed signs of
portal hypertension including; oesophageal varices (n = 3) and sple-
nomegaly (n = 3) and collateral veins (n = 1). In addition, splenome-
galy was present in one noncirrhotic AIH‐PSC patient who was
treated with AZA 125 mg/day, 1 year prior to initiation of TG ther-
apy. None of the patients had a history of variceal bleeding or
ascites. No development of portal hypertension or associated events
were recorded in patients while they were treated with TG.
3.2 | TG Efficacy in AIH patients
Thirty‐three AIH patients were treated with TG after intolerable side
effects on AZA or MP (Table 2). At the time of last follow‐up, TG





N 42 6 4
Characteristics at diagnosis
Female (%) 79 33 100
Age (y) 47 (11‐71) 32.5 (16‐59) 61 (24‐67)
ALT (U/L) 558 (57‐2214) 107 (38‐182) 152 (78‐1418)
















16 (8‐21) 17 (10‐19) 13 (7‐15)
Study baseline
Cirrhosis %,
n biopsied 19%, 40 0%, 6 0%, 3
Months
diagnosed
18 (0‐280) 57 (10‐190) 31 (2‐46)
Tioguanine therapy
Initial dose
mg kg−1 d−1 0.23 (0.10‐0.33) 0.27 (0.18‐0.32) 0.29 (0.27‐0.38)
mg/d 20 (10‐24) 21 (10‐24) 20 (18‐24)
Dose at last
use (mg/d)




12 (2‐194) 9 (3‐97) 83 (18‐93)
ALT: alanine aminotransferase; AMA: anti‐mitochondrial antibodies;
ANA: anti‐nuclear antibody; IgG: immunoglobulin G; LKM‐1: liver kidney
microsomal antibody; SLA/LP: soluble liver antigen/liver and pancreas
antibody; SMA: smooth muscle antibody.
aPost‐treatment revised International AIH Group score.10
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therapy was continued in 26 patients for a median of 22 months
(range 3‐194). Biochemical measurements showed complete biochemi-
cal remission, incomplete response and nonresponse in 22 (85%), three
(11%) and one (4%) patient respectively. Seven (21%) of the 33
patients discontinued treatment due to intolerable side‐effects (after
months 2, 5, 9 and 24), noncompliance (after 2 months), nonresponse
(after 7 months); one patient was offered a trial of withdrawal after
sustained remission according to recent guidelines.1
Insufficient response on AZA or MP was the reason for switch in
six AIH patients; four were responsive to TG therapy, two had com-
plete and two had incomplete biochemical remission; two discontin-
ued due to intolerance and nonresponse after 5 and 18 months
respectively.
Early biochemical response to TG therapy was measured at 1 and
3 months. At baseline 9 of 39 (23%) patients had complete biochemi-
cal remission; this increased to 19 of 38 (50%, P = 0.002), and 19 of
34 (56%, P < 0.001) after 1 and 3 months, respectively (Table 3).
Serum ALT levels are shown in Figure 1. The median IgG levels were
similar at 1, 3 and 12 months compared with baseline (Figure 2).
Prednisolone or budesonide was used by 32 (87%) patients at
the time of initiation of TG therapy. A decrease in glucocorticoid
dose of >25% was achieved in 18 (56%) patients at the last follow‐
up. Complete withdrawal of steroids was achieved in six of these
patients. Two (6%) patients required a steroid dose escalation. Ster-
oids were initiated in another two (6%) patients.
Two AIH patients who were in remission for 1 year, temporarily
discontinued TG, one patient in a drug withdrawal attempt as agreed
with the treating physician and another patient refused to switch
between two brands of TG. Both relapsed after 3 and 18 months
respectively. After remission was induced with prednisone, complete
biochemical remission was again maintained with TG monotherapy
(20 mg/day) in both patients with a follow‐up of 6 months.
3.3 | AIH variant syndromes
Treatment details of 10 patients with AIH variant syndromes who
failed on conventional treatment are depicted in Table 4 and include
six AIH‐PSC, two AIH‐PBC and two AMA negative AIH‐PBC
patients. TG therapy was initiated in two patients after insufficient
response on prednisone combined with mycophenolate mofetil and
tacrolimus (patient two) or ciclosporin (patient seven). Patient nine
and 10 had toxic 6‐methyl MP levels of >5.700 pmol/8 × 108 red
blood cells on conventional thiopurines respectively. Six out of 10
patients achieved complete biochemical remission on TG therapy
(Figure 3). At the last follow‐up five AIH variant patients had discon-
tinued TG therapy for various reasons (Table 4).
The median alkaline phosphatase at diagnosis of AIH variant
patients was 258 U/L (range 74‐757). Alkaline phosphatase levels
during TG therapy are shown in Figure S1.
3.4 | First‐line maintenance therapy
In three patients with established AIH10 (post‐treatment International
AIH Group scores of 13‐16), TG was initiated as the first steroid
sparing agent, based on the judgement of the treating physician. TG
therapy was initiated after diagnosis in two and after a flare while
on monotherapy budesonide in another.
Two patients achieved complete biochemical remission after
6 months of TG therapy, which led to complete withdrawal of
budesonide in one patient and tapering of prednisolone from 30 to
10 mg/day in the other. The third patient was followed for 1 month,
in which she tolerated TG treatment.
3.5 | Cirrhosis in AIH and AIH variant patients
Cirrhosis was present in eight (16%) and fibrosis in 22 (45%) of 49
patients who were biopsied prior to TG therapy. Two patients were
not biopsied at diagnosis, due to coagulopathy and the histology report
of another patient could not be retrieved. Twenty‐eight biopsies were
performed in 10 patients on TG therapy, after a median treatment of
56 months (range 10‐111). Progression from fibrosis to cirrhosis
occurred in one of the 10 biopsied patients. Of relevance, there were
no cases of nodular regenerative hyperplasia identified in histology.
3.6 | Drug adherence in AIH and AIH variant
patients
In 30 patients, a total of 51 serum 6‐TGN levels were measured at
least 4 weeks after first TG administration. Twenty‐nine patients
were adherent to TG therapy with median 6‐TGN levels of 746
(range 168‐3070) pmol/8 × 108 red blood cells. One patient who
was noncompliant after experiencing intolerable side effects and had
undetectable 6‐TGN levels.
TABLE 2 Tolerable and intolerable adverse events on AZA, MP
and TG therapy
AZA or MP (N = 49) TG (N = 52)
Tolerable Intolerable Tolerable Intolerable
Patients with an AE 6 38 4 7
Nausea and vomiting 6 20 1
Headache 2 1 2
Fatigue 2 7 1
Myalgia/arthralgia 1 6 3
Itch 1 1
Rash 1 1
Abdominal pain 1 3 1





Myelotoxicity 2 4 1
AE: adverse event; AZA: azathioprine; MP: mercaptopurine; TG: tiogua-
nine.
Patients could report multiple side effects.
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4 | DISCUSSION
The conventional thiopurines AZA and MP have been successfully
used for decades in the treatment of various immune mediated dis-
eases, including inflammatory bowel disease and AIH. Nevertheless,
about 20% of patients do not respond to conventional thiopurines,
which can be attributed in part to an unfavourable metabolism
resulting in high levels of breakdown products associated with sev-
eral side effects and low levels of the active metabolites. Similarly,
many patients do not tolerate these drugs. TG has the advantage
that it does not require metabolic steps in order to become active
and in inflammatory bowel disease, this drug has proven to be an
attractive alternative in these patients.17,18 So far, evidence that sup-
ports this strategy in AIH is lacking. In this largest retrospective
study to date, we report the efficacy and tolerability of TG therapy
in 52 patients with AIH and AIH variant syndromes treated in nine
referral and tertiary hospitals in the Netherlands. Results demon-
strate that TG therapy is well tolerated and clinically effective in
patients who previously failed on AZA or MP. In addition, TG ther-
apy was effective and tolerated in three thiopurine naïve patients.
Our data show that the vast majority of patients with AIH and
AIH variants with prior intolerable side effects on conventional
thiopurines will tolerate TG therapy. Similarly, nearly all patient‐
reported tolerable side effects disappeared after switching to TG
therapy. The side effects reported on TG therapy differed from
those reported on the original thiopurine and switching resulted in
normalisation of full blood count outcomes in all but one patient
with myelosuppression in our cohort, which is supported by recent
data in the field of inflammatory bowel disease.4,19 The favourable
tolerability might be explained by the one‐step metabolism of TG
into the pharmacologically effective 6‐TGNs, without the formation
of potentially toxic 6‐methyl MP metabolites seen in the complex
metabolism of AZA and MP. Although this metabolism can effec-
tively be skewed towards 6‐TGN formation by adding low‐dose
allopurinol or mesalazine,20 direct TG therapy would prevent addi-
tion of another drug.
In our cohort, TG was effective in the majority (85%) of AIH
patients with prior intolerance on conventional thiopurines. This is in
line with a recent small single centre study, where 17 AIH patients
who had failed on AZA were switched to TG.9 Although switching
patients from one thiopurine to another after incomplete response
was ineffective in prior studies,9,21 two AIH and two AIH‐PSC
patients in our cohort achieved complete biochemical remission with
TG therapy after insufficient response on other thiopurines.
Patients with AIH who fail AZA have limited rescue options with
the most frequently used second line treatment being mycopheno-
late mofetil. The success rate of TG therapy in our cohort was
slightly higher compared to mycophenolate mofetil for those patients
who switched due to intolerable side effects (85% vs 43%‐75%) or
due to insufficient response on conventional thiopurines (50% vs
TABLE 3 Early response on rescue treatment with tioguanine in AIH patients
Months of treatment Follow‐up n
Tioguanine therapy Biochemical response
P‐valueaStopped n Ongoing n Incomplete n (%) Complete n (%)
Baseline 39 0 39 — 9 (23)
1 38 0 38 19 (50) 19 (50) 0.002
3 36 2 34 15 (44) 19 (56) <0.001
aCompared with complete biochemical response at baseline.









P < 0.0001 P = 0.005 P < 0.001* 403
* 344
F IGURE 1 Serum alanine aminotransferase (ALT) in patients with
autoimmune hepatitis before and after 1, 3 and 12 mo of tioguanine
therapy. The dotted line represents the upper value of normal for
female patients










P = 0.1 P = 0.7 P = 0.6
F IGURE 2 Serum immunoglobulin G (IgG) in patients with
autoimmune hepatitis before and after 1, 3 and 12 mo of tioguanine
therapy. The dotted line represents the upper value of normal
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20%‐34%).22–24 A multicentre study with a considerable experience
in AIH patients (n = 105) treated with mycophenolate mofetil
reported 25% tolerable and 9% intolerable side effects, which is
comparable to our data in patients using TG.24 Serious adverse
events occurred in three patients using mycophenolate mofetil,
which we did not observe in our cohort.
Metabolite measurements show that all but one of the patients
tested were adherent to TG therapy, confirming that this is a useful
tool for adherence monitoring, but due to infrequent 6‐TGN mea-
surements, insufficient data was available for dose‐response and tox-
icity profiles analyses.
Concerns regarding nodular regenerative hyperplasia were not
substantiated in this cohort, in which despite available histological
follow‐up no cases were identified. This can be explained by the rel-
atively low dose compared with the original oncological and inflam-
matory bowel disease studies in which nodular regenerative
hyperplasia was identified. Moreover, a review in patients with
inflammatory bowel disease showed that considerably less nodular
regenerative hyperplasia occurred when dosages of TG did not
exceed 25 mg/day.7 In addition, no association was found between
nodular regenerative hyperplasia and clinically significant liver dis-
ease, in a recent inflammatory bowel disease study.25 There were no
cases of pancreatitis in our cohort.
This study encompasses experience on a national‐level leading to
generalisable results of AIH patients who received TG therapy. Other
strengths of this study are the large number of patients in a real‐life
cohort, the strict complete biochemical remission and the separate
analysis of variant syndromes. It should be noted that this study was
not powered for safety analysis and despite measures to control for
ascertainment bias, adverse events may have been missed. Due to
the retrospective nature of this study, it was not possible to control
for co‐medication which might have biased the response rate. How-
ever, corticosteroid dose could be decreased in most patients, while
maintaining remission.
In conclusion, our data show that TG therapy with a median
dose of 20 mg/day is tolerated and leads to complete biochemical
remission in selected patients with AIH or AIH variants who were
previously intolerant and in some patients with prior insufficient
response on conventional thiopurines.

















1 AIH‐PSC 17, m Nonresponse, AZA/MP 21 3 Nonresponse No 20 20 UDCA (14 mg/kg)
2 AIH‐PSC 40, f Nonresponse, AZA 21 31 Incomplete Yes 10 7.5 UDCA (12 mg/kg,
tacrolimus
3 AIH‐PSC 40, f Nonresponse, AZA/MP 24 97 Incomplete Noa 10 2.5 UDCA (14 mg/kg)
4 AIH‐PSC 51, m Nonresponse and
intolerance, AZA
20 11 Complete Intolerant 30 5 UDCA (24 mg/kg)
5 AIH‐PSC 67, m Intolerance, AZA 10 3 Incomplete Yes 10 — —
6 AIH‐PSC 29, m Intolerance, AZA 20 5 Complete Yes — 10 UDCA (13 mg/kg)
7 AIH‐PBC 67, f Nonresponse and
intolerance, MP
20 86 Complete Yes 30 10 UDCA (13 mg/kg),
ciclosporin
8 AIH‐PBC 67, f Intolerance, AZA 20 93 Complete Yes — — UDCA (18 mg/kg)
9 AMA neg.
AIH‐PBC
62, f Toxic levels and
intolerance, AZA/MP




27, f Toxic levels, AZA 24 80 Complete Noc 30 — UDCA (19 mg/kg)
AZA: azathioprine; f: female; m: male; MP: mercaptopurine; UDCA: ursodeoxycholic acid.
aInitially, nodular regenerative hyperplasia was suspected in histology, however, review of the histology by two hepatopathologists did not confirm this.
bBudesonide (6 mg/d) was fully tapered.
cA trial of withdrawal was offered after more than 2 years of complete biochemical remission on tioguanine monotherapy, according to recent guidelines.1
























F IGURE 3 The effect of tioguanine therapy on alanine
aminotransferase (ALT) levels in patients with AIH‐PSC, AIH‐PBC
and anti‐mitochondrial antibody negative AIH‐PBC. The dotted line
represents the upper value of normal for female patients
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